Targeting the conformational transitions of MDM2 and MDMX: Insights into key residues affecting p53 recognition

Proteins: Structure, Function and Bioinformatics

Volumn 77, Issue 3, 2009, Pages 524-535

  Carotti, Andrea ^a   Macchiarulo, Antonio ^a   Giacchè, Nicola ^a   Pellicciari, Roberto ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Cancer; MDM2; MDMX; Molecular dynamics; p53

Indexed keywords

PROTEIN MDM2; PROTEIN MDMX; PROTEIN P53;

ARTICLE; CONFORMATIONAL TRANSITION; MOLECULAR DYNAMICS; MOLECULAR RECOGNITION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; PROTEIN SECONDARY STRUCTURE; PROTEIN STRUCTURE; SIMULATION;

BINDING SITES; COMPUTATIONAL BIOLOGY; HUMANS; MODELS, MOLECULAR; NEOPLASMS; NUCLEAR PROTEINS; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN INTERACTION MAPPING; PROTEIN STRUCTURE, SECONDARY; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; SOFTWARE; STATIC ELECTRICITY; TUMOR SUPPRESSOR PROTEIN P53;

EID: 70349328272     PISSN: 08873585     EISSN: 10970134     Source Type: Journal    
DOI: 10.1002/prot.22464     Document Type: Article

References (68)

1. Wahl GM. Mouse bites dogma: how mouse models are changing our views of how P53 is regulated in vivo. Cell Death Differ 2006;13:973-983.
2. Naski N, Gajjar M, Bourougaa K, Malbert-Colas L, Fahraeus R, Candeias MM. The p53 mRNA-Mdm2 interaction. Cell Cycle 2009;8:31-34.
3. Perry ME. Mdm2 in the response to radiation. Mol Cancer Res 2004;2:9-19.
4. Shvarts A, Steegenga WT, Riteco N, van Laar T, Dekker P, Bazuine M, van Ham RC, van der Houve van Oordt , Hateboer G, van der Eb AJ, Jochemsen AG. MDMX: a novel p53-binding protein with some functional properties of MDM2. EMBO J 1996;15:5349-5357. (Pubitemid 26336217)
5. Candeias MM, Malbert-Colas L, Powell DJ, Daskalogianni C, Maslon MM, Naski N, Bourougaa K, Calvo F, Fahraeus R. p53 mRNA controls p53 activity by managing Mdm2 functions. Nat Cell Biol 2008;10:1098-1105.
6. Pan Y, Chen J. MDM2 promotes ubiquitination and degradation of MDMX. Mol Cell Biol 2003;23:5113-5121. (Pubitemid 36950868)
7. Kawai H, Wiederschain D, Kitao H, Stuart J, Tsai KK, Yuan ZM. DNA damage-induced MDMX degradation is mediated by MDM2. J Biol Chem 2003;278:45946-45953. (Pubitemid 37432741)
8. de Graaf P, Little NA, Ramos YF, Meulmeester E, Letteboer SJ, Jochemsen AG. Hdmx protein stability is regulated by the ubiquitin ligase activity of Mdm2. J Biol Chem 2003;278:38315-38324. (Pubitemid 37221723)
9. Francoz S, Froment P, Bogaerts S, De Clercq S, Maetens M, Doumont G, Bellefroid E, Marine JC. Mdm4 and Mdm2 cooperate to inhibit p53 activity in proliferating and quiescent cells in vivo. Proc Natl Acad Sci USA 2006;103:3232-3237. (Pubitemid 43346453)
10. Xiong S, Van Pelt CS, Elizondo-Fraire AC, Liu G, Lozano G. Synergistic roles of Mdm2 and Mdm4 for p53 inhibition in central nervous system development. Proc Natl Acad Sci USA 2006;103:3226-3231. (Pubitemid 43346452)
11. Marine JC, Jochemsen AG. Mdmx as an essential regulator of p53 activity. Biochem Biophys Res Commun 2005;331:750-760.
12. Parant J, Chavez-Reyes A, Little NA, Yan W, Reinke V, Jochemsen AG, Lozano G. Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53. Nat Genet 2001;29:92-95. (Pubitemid 32801817)
13. Migliorini D, Lazzerini DE, Danovi D, Jochemsen A, Capillo M, Gobbi A, Helin K, Pelicci PG, Marine JC. Mdm4 (Mdmx) regulates p53-induced growth arrest and neuronal cell death during early embryonic mouse development. Mol Cell Biol 2002;22:5527-5538. (Pubitemid 34755762)
14. Finch RA, Donoviel DB, Potter D, Shi M, Fan A, Freed DD, Wang CY, Zambrowicz BP, Ramirez-Solis R, Sands AT, Zhang N. mdmx is a negative regulator of p53 activity in vivo. Cancer Res 2002;62:3221-3225. (Pubitemid 34602417)
15. Jones SN, Roe AE, Donehower LA, Bradley A. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 1995;378:206-208.
16. Montes de Oca LR, Wagner DS, Lozano G. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 1995;378:203-206.
17. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000;408:307-310.
18. Vousden KH, Lane DP. p53 in health and disease. Nat Rev Mol Cell Biol 2007;8:275-283.
19. Toledo F, Wahl GM. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer 2006;6:909-923. (Pubitemid 44862676)
20. Ramos YF, Stad R, Attema J, Peltenburg LT, van der Eb AJ, Jochemsen AG. Aberrant expression of HDMX proteins in tumor cells correlates with wild-type p53. Cancer Res 2001;61:1839-1842. (Pubitemid 32691995)
21. Laurie NA, Donovan SL, Shih CS, Zhang J, Mills N, Fuller C, Teunisse A, Lam S, Ramos Y, Mohan A, Johnson D, Wilson M, Rodriguez-Galindo C, Quarto M, Francoz S, Mendrysa SM, Guy RK, Marine JC, Jochemsen AG, Dyer MA. Inactivation of the p53 pathway in retinoblastoma. Nature 2006;444:61-66.
22. Halatsch ME, Schmidt U, Unterberg A, Vougioukas VI. Uniform MDM2 overexpression in a panel of glioblastoma multiforme cell lines with divergent EGFR and p53 expression status. Anticancer Res 2006;26:4191-4194. (Pubitemid 46031490)
23. Wade M, Wong ET, Tang M, Stommel JM, Wahl GM. Hdmx modulates the outcome of p53 activation in human tumor cells. J Biol Chem 2006;281:33036-33044. (Pubitemid 46036686)
24. Hu B, Gilkes DM, Farooqi B, Sebti SM, Chen J. MDMX overexpression prevents p53 activation by the MDM2 inhibitor Nutlin. J Biol Chem 2006;281:33030-33035. (Pubitemid 46036685)
25. Patton JT, Mayo LD, Singhi AD, Gudkov AV, Stark GR, Jackson MW. Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3. Cancer Res 2006;66:3169-3176.
26. Wells JA, McClendon CL. Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature 2007;450:1001-1009.
27. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, Fotouhi N, Liu EA. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004;303:844-848.
28. Grasberger BL, Lu T, Schubert C, Parks DJ, Carver TE, Koblish HK, Cummings MD, LaFrance LV, Milkiewicz KL, Calvo RR, Maguire D, Lattanze J, Franks CF, Zhao S, Ramachandren K, Bylebyl GR, Zhang M, Manthey CL, Petrella EC, Pantoliano MW, Deckman IC, Spurlino JC, Maroney AC, Tomczuk BE, Molloy CJ, Bone RF. Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells. J Med Chem 2005;48:909-912. (Pubitemid 40270436)
29. Fry DC, Emerson SD, Palme S, Vu BT, Liu CM, Podlaski F. NMR structure of a complex between MDM2 and a small molecule inhibitor. J Biomol NMR 2004;30:163-173. (Pubitemid 39549733)
30. Kussie PH, Gorina S, Marechal V, Elenbaas B, Moreau J, Levine AJ, Pavletich NP. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 1996;274:948-953. (Pubitemid 26398409)
31. Uhrinova S, Uhrin D, Powers H, Watt K, Zheleva D, Fischer P, McInnes C, Barlow PN. Structure of free MDM2 N-terminal domain reveals conformational adjustments that accompany p53-binding. J Mol Biol 2005;350:587-598. (Pubitemid 40828916)
32. Fasan R, Dias RL, Moehle K, Zerbe O, Obrecht D, Mittl PR, Grutter MG, Robinson JA. Structure-activity studies in a family of β-hairpin protein epitope mimetic inhibitors of the p53-HDM2 protein-protein interaction. Chembiochem 2006;7:515-526.
33. Sakurai K, Schubert C, Kahne D. Crystallographic analysis of an 8-mer p53 peptide analogue complexed with MDM2. J Am Chem Soc 2006;128:11000-11001. (Pubitemid 44300090)
34. Popowicz GM, Czarna A, Rothweiler U, Szwagierczak A, Krajewski M, Weber L, Holak TA. Molecular basis for the inhibition of p53 by Mdmx. Cell Cycle 2007;6:2386-2392. (Pubitemid 350064092)
35. Popowicz GM, Czarna A, Holak TA. Structure of the human Mdmx protein bound to the p53 tumor suppressor transactivation domain. Cell Cycle 2008;7:2441-2443.
36. Ding Y, Mei Y, Zhang JZ. Quantum mechanical studies of residue-specific hydrophobic interactions in p53-MDM2 binding. J Phys Chem B 2008;112:11396- 11401.
37. Espinoza-Fonseca LM, Garcia-Machorro J. Aromatic-aromatic interactions in the formation of the MDM2-p53 complex. Biochem Biophys Res Commun 2008;370:547-551.
38. Lee HJ, Srinivasan D, Coomber D, Lane DP, Verma CS. Modulation of the p53-MDM2 interaction by phosphorylation of Thr18: a computational study. Cell Cycle 2007;6:2604-2611. (Pubitemid 350224041)
39. Chen HF, Luo R. Binding induced folding in p53-MDM2 complex. J Am Chem Soc 2007;129:2930-2937. (Pubitemid 46417970)
40. Espinoza-Fonseca LM, Trujillo-Ferrara JG. Conformational changes of the p53-binding cleft of MDM2 revealed by molecular dynamics simulations. Biopolymers 2006;83:365-373.
41. Zhong H, Carlson HA. Computational studies and peptidomimetic design for the human p53-MDM2 complex. Proteins 2005;58:222-234. (Pubitemid 39665633)
42. Ma B, Pan Y, Gunasekaran K, Venkataraghavan RB, Levine AJ, Nussinov R. Comparison of the protein-protein interfaces in the p53-DNA crystal structures: towards elucidation of the biological interface. Proc Natl Acad Sci U S A 2005;102:3988-3993. (Pubitemid 40388543)
43. Pan Y, Nussinov R. Structural basis for p53 binding-induced DNA bending. J Biol Chem 2007;282:691-699. (Pubitemid 47076607)
44. Pan Y, Nussinov R. p53-Induced DNA bending: the interplay between p53-DNA and p53-p53 interactions. J Phys Chem B 2008;112:6716-6724.
45. Lu Q, Tan YH, Luo R. Molecular dynamics simulations of p53 DNA-binding domain. J Phys Chem B 2007;111:11538-11545. (Pubitemid 47598337)
46. Pan Y, Ma B, Levine AJ, Nussinov R. Comparison of the human and worm p53 structures suggests a way for enhancing stability. Biochemistry 2006;45:3925-3933.
47. Dastidar SG, Lane DP, Verma CS. Multiple peptide conformations give rise to similar binding affinities: molecular simulations of p53-MDM2. J Am Chem Soc 2008;130:13514-13515.
48. Macchiarulo A, Giacche N, Carotti A, Baroni M, Cruciani G, Pellicciari R. Targeting the conformational transitions of MDM2 and MDMX: insights into dissimilarities and similarities of p53 recognition. J Chem Inf Model 2008;48:1999-2009.
49. Lindahl E, Hess B, van der Spoel D. GROMACS 3.0: a package for molecular simulation and trajectory analysis. J Mol Model 2001;7:306-317. (Pubitemid 36153547)
50. MacKerell AD. Developments in the CHARMM all-atom empirical energy function for biological molecules. Abstr Papers Am Chem Soc 1998;216:U696.
51. Phillips JC, Braun R, Wang W, Gumbart J, Tajkhorshid E, Villa E, Chipot C, Skeel RD, Kale L, Schulten K. Scalable molecular dynamics with NAMD. J Comput Chem 2005;26:1781-1802.
52. Weber W, Hunenberger PH, McCammon JA. Molecular dynamics simulations of a polyalanine octapeptide under Ewald boundary conditions: influence of artificial periodicity on peptide conformation. J Phys Chem B 2000;104:3668-3675. (Pubitemid 30858506)
53. Essmann U, Perera L, Berkowitz ML, Darden T, Lee H, Pedersen LG. A Smooth Particle Mesh Ewald Method. J Chem Phys 1995;103:8577-8593.
54. Darden T, York D, Pedersen L. Particle mesh Ewald - an N. Log(N) method for Ewald sums in large systems J Chem Phys 1993;98:10089-10092.
55. Van Gunsteren WF, Berendsen HJC. Algorithms for macromolecular dynamics and constraint dynamics. Mol Phys 1977;5:1311-1327.
56. Keskin O, Gursoy A, Ma B, Nussinov R. Principles of protein-protein interactions: what are the preferred ways for proteins to interact? Chem Rev 2008;108:1225-1244.
57. McCoy MA, Gesell JJ, Senior MM, Wyss DF. Flexible lid to the p53-binding domain of human Mdm2: implications for p53 regulation. Proc Natl Acad Sci USA 2003;100:1645-1648.
58. Bottger V, Bottger A, Garcia-Echeverria C, Ramos YF, van der Eb AJ, Jochemsen AG, Lane DP. Comparative study of the p53-mdm2 and p53-MDMX interfaces. Oncogene 1999;18:189-199. (Pubitemid 29060593)
59. Showalter SA, Bruschweiler-Li L, Johnson E, Zhang F, Bruschweiler R. Quantitative lid dynamics of MDM2 reveals differential ligand binding modes of the p53-binding cleft. J Am Chem Soc 2008;130:6472-6478. (Pubitemid 351706110)
60. Pazgier M, Liu M, Zou G, Yuan W, Li C, Li C, Li J, Monbo J, Zella D, Tarasov SG, Lu W. Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX. Proc Natl Acad Sci USA 2009;106:4665-4670.
61. Ding K, Lu Y, Nikolovska-Coleska Z, Wang G, Qiu S, Shangary S, Gao W, Qin D, Stuckey J, Krajewski K, Roller PP, Wang S. Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction. J Med Chem 2006;49:3432-3435. (Pubitemid 43902447)
62. Fisher RA. The use of multiple measurement in taxonomic problems. Ann Eugenics 1936;7:179-188.
63. Fisher RA. The statistical utilization of multiple measurements. Annals of Eugen 1938;8:376-386.
64. Duda R, Hart P, Stork D. Pattern classification. New York: John Wiley & Sons; 2001. 680 p.
65. Yu GW, Vaysburd M, Allen MD, Settanni G, Fersht AR. Structure of human MDM4 N-terminal domain bound to a single-domain antibody. J Mol Biol 2009;385:1578-1589.
66. Kallen J, Goepfert A, Blechschmidt A, Izaac A, Geiser M, Tavares G, Ramage P, Furet P, Masuya K, Lisztwan J. Crystal structures of human MdmX (HdmX) in complex with p53 peptide-analogues reveal surprising conformational changes. J Biol Chem 2009;284:8812-8821.
67. Zuckerman V, Lenos K, Popowicz GM, Silberman I, Grossman T, Marine JC, Holak TA, Jochemsen AG, Haupt Y. c-Abl phosphorylates Hdmx and regulates its interaction with p53. J Biol Chem 2009;284:4031-4039.
68. Czarna A, Popowicz GM, Pecak A, Wolf S, Dubin G, Holak TA. High affinity interaction of the p53 peptide-analogue with human Mdm2 and Mdmx. Cell Cycle 2009;8:1176-1184.